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ABSTRACT
Cancer-induced bone pain (CIBP) is common in patients with bone metastases 
(BM), significantly impairing quality of life. The current treatments for CIBP are limited 
since they are often ineffective. Local acidosis derived from glycolytic carcinoma and 
tumor-induced osteolysis is only barely explored cause of pain. We found that breast 
carcinoma cells that prefer bone as a metastatic site have very high extracellular proton 
efflux and expression of pumps/ion transporters associated with acid-base balance 
(MCT4, CA9, and V-ATPase). Further, the impairment of intratumoral acidification via 
V-ATPase targeting in xenografts with BM significantly reduced CIBP, as measured by 
incapacitance test. We hypothesize that in addition to the direct acid-induced stimulation 
of nociceptors in the bone, a novel mechanism mediated by the acid-induced and tumor-
associated mesenchymal stroma might ultimately lead to nociceptor sensitization 
and hyperalgesia. Consistent with this, short-term exposure of cancer-associated 
fibroblasts, mesenchymal stem cells, and osteoblasts to pH 6.8 promotes the expression 
of inflammatory and nociceptive mediators (NGF, BDNF, IL6, IL8, IL1b and CCL5). This 
is also consistent with a significant correlation between breakthrough pain, measured 
by pain questionnaire, and combined high serum levels of BDNF and IL6 in patients 
with BM, and also by immunofluorescence staining showing IL8 expression that was 
more in mesenchymal stromal cells rather than in tumors cells, and close to LAMP-2 
positive acidifying carcinoma cells in BM tissue sections.
In summary, intratumoral acidification in BM might promote CIBP also by 
activating the tumor-associated stroma, offering a new target for palliative treatments 
in advanced cancer.
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INTRODUCTION
Skeletal involvement is a frequent and troublesome 
complication affecting many patients with advanced 
cancer. Bone is the third most common metastatic site [1]: 
up to 85% of patients that die from breast, prostate, or lung 
cancer have bone involvement at autopsy [2, 3]. Once tumor 
cells become housed in the skeleton, the disease is usually 
considered incurable, and treatment is only palliative. 
One of the most intolerable symptoms is cancer-induced 
bone pain (CIBP), which has a strong impact on quality 
of life. CIBP causes difficulty in ambulation, neurologic 
deficits, depression, and anxiety. Current therapies based 
on radiotherapy, non-steroidal anti-inflammatory drugs 
(NSAIDs), bisphosphonates, and opioids are often in-
effective and cause unacceptable side effects [3-5]. Opioids 
often cause excessive sedation and lack of responsiveness, 
and a strong evidence base for the use of NSAIDs is still 
lacking [6]. Therefore, new and effective palliative measures 
are required to maintain an acceptable quality of life.
A novel approach focusing on recent insights into the 
molecular mechanisms of CIBP and the peculiar features 
of the microenvironment of bone metastases (BM) might 
help improve therapy options. The pathophysiology of bone 
pain is unique and complex [7]. CIBP is a mixed type of 
chronic pain involving both inflammatory nociceptive and 
neuropathic pain, and it can be breakthrough, a transitory 
flare of pain in the setting of chronic pain managed 
with opioid drugs. Neuropathic pain is evoked by the 
compression and invasion of sensory nerves by cancer cells, 
whereas mechanical pain is induced by the stretching of the 
periosteum for tumor expansion, or by microfractures that 
occur as a consequence of increased bone resorption [2, 8]. 
Sensory neurons (nociceptors) densely innervate the bone 
marrow and the periosteal surfaces of the cortical bone and 
can sense diverse noxious stimuli. Nociceptors are activated 
through acid-sensing receptors, [i.e, acid-sensing ion channels 
(ASICs) and the transient receptor potential channel-vanilloid 
subfamily members (TRPVs)] [9]. Therefore, protons are 
important mediators of nociceptor stimulation to evoke an 
allogenic signal [10, 11]. Local acidosis is common in BM 
and is independent of the inflammatory reaction, because it 
derives from the extracellular acidification caused by inter 
alia, mesenchymal stromal cells, bone-resorbing osteoclasts, 
and metastatic cancer cells. The relative contributions of these 
diverse sources of acid to CIBP are not well characterized. 
Because of their elevated level of aerobic glycolysis, 
aggressive cancer cells secrete substantial amounts of 
protons [12] through an armamentarium of pumps and 
transporters, including vacuolar H+-ATPase (V-ATPase) 
that is directly associated with tumor invasion and metastasis 
[12, 13]. Further, tumor can induce osteoclasts that dissolve 
bone through the secretion of large amounts of protons, 
also via V-ATPase, into the resorption lacunae, reaching 
pH levels around 4.5 [14]. Thus, these large amounts of 
protons in the extracellular space can directly stimulate 
nociceptors through acid-sensing ion channels. We explored 
intratumoral acidification as a novel target for palliative 
treatment in patients with BM also by investigating on the 
role of mesenchymal stromal cells in mediating nociceptive 
stimulation in the acidic BM microenvironment.
RESULTS
Breast carcinoma cells that prefer the bone as a 
metastatic site strongly acidify the extracellular 
microenvironment
Breast carcinoma cells strongly acidify the tumor 
microenvironment [15]. Such acidification might promote 
the pathogenic process in bone; however, the association 
between the ability to localize in the bone and the ability to 
secrete high levels of protons has never been evaluated. We 
compared the MDA cell line with the bmMDA clone, which 
is more prone to form BM when injected into the left ventricle 
of nude mice [16]. Compared with the parental MDA cells, the 
bmMDA cells showed higher mRNA (Figure 1A) expression 
of key regulators of intracellular pH [12, 17], such as carbonic 
anhydrase 9 (CA9; mRNA p = 0.0209) and monocarboxylate 
transporter 4 (MCT4; mRNA p=0.0209, protein p=0.0495), and 
glucose transporter 1 (GLUT-1; mRNA p=0.045), an indirect 
marker of glycolysis. Results were confirmed also at protein 
level for MCT4 (Figure 1B). Moreover, the supernatants of 
the bmMDA cultures displayed greater release of L-Lactate 
(p=0.0209; Figure 1C). Further, a reduced-oxygen condition 
enhanced the mRNA expression of the analyzed genes and 
the release of L-Lactate (Figure 1A and 1C).
In association with the increased glycolytic activity and 
lactate release, the bmMDA cells accumulated more protons in 
the lysosomes and extruded more protons into the extracellular 
space than the parental MDA cells. Compared with the MDA 
cells, the bmMDA cells has significantly more pumped protons 
(pH decrement, p=0.0476 Figure 1D), and expressed a higher 
level of the V-ATPase, especially under hypoxia for the V1B2 
and V0C subunits, or already at normoxia for the V1G1 subunit 
(p=0.0209, p=0.0209, and p=0.0495, respectively; Figure 
1E). These results suggested that the breast carcinoma cells 
that are more prone to metastasize to the bone are positively 
selected from the original tumor-cell population based on their 
pronounced aptitude to release protons outside the cell. The 
extracellular acidification by breast cancer cells and tumor-
induced osteoclasts could thus be directly responsible for the 
stimulation of acid-sensing ion channels in the nociceptors that 
innervate the bone, ultimately leading to bone pain.
The targeting of intratumoral acidification 
reduces CIBP
Omeprazole, a gastric H+/K(+)-ATPase inhibitor 
that can also block V-ATPase [18] has recently sparked 
great interest in relation to extracellular acidification in 
tumors. Acridine orange staining and spectroconfocal 
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microscopy verified that the treatment effectively inhibited 
lysosomal acidification both in human osteoclasts and 
in bmMDA cells (p=0.023 and p=0.0373, respectively; 
Figure 1F and 1G, Supplementary Figure 1). We evaluated 
the effect of omeprazole on CIBP in vivo (Figure 2) with 
intratibially injected bmMDA. The omeprazole treatment 
did not alter tumor-promoted osteolysis (Figure 2B) 
since, with the exception of the last endpoint, a non-
significant trend of reduction in the area of osteolytic 
lesions was observed (Figure 2B). However, omeprazole 
Figure 1: Breast carcinoma bmMDA cells show a higher glycolytic metabolism with a higher extracellular acidification 
activity than the parental MDA. (A) mRNA analysis of CA9, GLUT1, and MCT4 expression under different O2 tensions. (N = 2 
technical and N = 3 biological replicates for GLUT1 and MCT4, and N = 2 technical and N = 2 biological replicates for CA9). (B) Western 
blotting analysis of MCT4 (upper panel, representative experiment; lower panel, densitometric quantification of N = 4 biological replicates); 
(C) L-Lactate concentration in the culture supernatants under different O2 tensions (N = 4 technical replicates); (D) pH decrement of the 
culture supernatant by electrode measurement (N = 6 biological replicates); (E) mRNA analysis of the expression of V-ATPase subunits 
under different O2 tensions (normoxia, normo; hypoxia, hypo) (N = 2 technical and N = 3 biological replicates for V1B2 and V1G1, and, 
N = 2 technical and N = 2 biological replicates for V0C); (F) Representative image of acridine orange staining (left panel) and graphical 
representation of the emission spectrum by confocal analysis (right panel) of all the lysosomes per cell of one representative osteoclast 
in the treated or not treated cultures with omeprazole; (G) lysosomal pH of cells treated with omeprazole as evaluated by acridine orange 
staining and spectral confocal microscopy and expressed as R% (N = 14 biological replicates). Mean ± SE, **p < 0.01 and *p < 0.05 for 
bmMDA vs MDA, and # p < 0.05 for normoxia (normo) vs hypoxia (hypo).
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treatment significantly reduced CIBP, as detected by the 
incapacitance tester. This type of assay measures changes 
in hind paw weight distribution between the right (tumor 
bearing) and left (contralateral control) limbs, a parameter 
that is correlated with pain (p=0.023; Figure 2C) [53].
Role of mesenchymal cells in acid-induced CIBP 
and hyperalgesia
We investigated the mechanism of the treatment-
resistant and hyperalgesic component of CIBP. We 
hypothesized that the tumor-associated mesenchymal 
stroma in the BM is involved in pain-related biological 
processes. As in vitro models, we used HOBs and MSCs 
from healthy donors, and CAFs isolated from BM 
biopsies. First, we assessed whether the mesenchymal cells 
of the BM microenvironment can detect the lowering of 
extracellular pH. MSCs, HOBs, and CAFs express ASIC4/
ACCN4, ASIC3/ACCN3, GPR65, and GPR4 at levels 
often comparable to or even higher to those expressed 
by cells of neuronal origin (Figure 3A). Notably, the 
ASIC4/ACCN4 and GPR65 levels in MSCs were further 
increased after a short (6 h) incubation under acidosis 
(p=0.0064 and p=0.025, respectively; Figure 3B). Thus, 
these data indicate that BM-associated mesenchymal cells 
have mechanisms in place to perceive the acidification of 
the BM microenvironment.
The incubation of MSCs at a low pH for 24 
h induced the mRNA transcription of nociceptive 
mediators (NGF and BDNF) and inflammatory 
cytokines (CCL20, CCL3, CCL5, IL15, IL1a, IL1b, 
IL23A, IL34, IL6, IL8, TNF, TGFA; Figure 4). Q-RT-
PCR in MSCs, HOBs, and CAFs partially confirmed 
the deep-sequencing results (Figure 5A); the low pH 
caused a significant increase in BDNF (MSCs p=0.025, 
HOBs p=0.0039, CAFs p=0.0209), NGF (HOBs 
p=0.0039, CAFs p=0.0209), CCL5 (MSCs p=0.0003, 
CAFs p=0.0209), IL1b (MSCs p=0.0039), IL6 
(MSCs p=0.0002, HOB p=0.0209, CAFs p=0.0202), 
and IL8 (MSCs p=0.0018, CAFs p=0.0356). The 
expression levels of the nociceptive mediators NGF 
and BDNF were higher than those in the tumor cell 
line bmMDA under acidosis (Figure 5B), and of cells 
of neuronal origin at pH 7.4 (Figure 5A). Protein 
Figure 2: In vivo treatment with omeprazole. bmMDA cells were inoculated by intratibial injection and then mice were treated with 
omeprazole (OME) or vehicle (VEH, 0.9% NaCl). (A) Schematic representation of the treatment; (B) Analysis of osteolytic areas evaluated 
via software image analyses (left panel) and representative x-ray scans (right panels, dashed line: osteolytic area); (C) Pain was evaluated 
by measuring changes in hind paw weight distribution (weight bearing) by using an incapacitance tester at different time points after tumor 
injection and during the treatment with omeprazole. Mice were placed in the measurement chamber of the incapacitance tester in an upright 
position, with the non-inoculated and inoculated limbs placed on 2 separate micro-scales. The changes in hind paw weight distribution was 
calculated by determining the difference (expressed as percent difference) in the amount of weight (G) between the left and right limbs. 
Mean ± SE, *p<0.05 vs vehicle treated. N=6 per group.
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analysis confirmed the secretion of IL6 and IL8 into the 
media (IL6 p=0.0177 for MSCs, p=0.0039 for HOBs, 
and p=0.0209 for CAFs; IL8: p=0.0116 for MSCs, 
p=0.0039 for HOBs, and p=0.0209 for CAFs; Figure 
5C). Furthermore, the induction of IL6 and IL8 mRNA 
expression by the low pH was very rapid, appearing 
after only 3 h in each cell type (Figure 6A), and was 
possibly mediated by NF-κB pathway activation 
because either NF-κB1, RelA, or RelB mRNA 
significantly increased at similar time-points, especially 
in the MSCs (Figure 6B). In contrast to untransformed 
cells, the breast cancer cells had a very low expression 
of the cytokines, at both at neutral (IL6: 0.004±0.002; 
IL8: 0.044±0.005) and acidic (IL6: 0.004±0.001; IL8: 
0.049±0.007) pH values.
Our data suggest a novel mechanistic model 
for untreatable CIBP that involves mesenchymal 
cells in patients with BM: the acidification of the BM 
microenvironment activates an auto-feeding process 
of pain by inducing of the secretion of nociceptive and 
inflammatory modulators from mesenchymal cells and 
thereby promoting hyperalgesia, leading ultimately to 
continuous sensitization of the nociceptors in the bone 
(Figure 7). The model matched evidence obtained from 
clinical samples. The serum levels of IL6 and IL8 in 
patients with BM of breast, lung and undefined carcinoma 
were significantly higher than those in healthy controls 
(p=0.0335 and p=0.0472, respectively; Figure 8A). 
Furthermore, although BDNF serum levels were lower 
in patients versus control (Figure 8B), high serum levels 
Figure 3: Expression of ion channels in BM-associated mesenchymal cells. (A) mRNA analysis of the basal level of expression 
of ACCN4, ACCN3, GPR65, and GPR4 in MSCs, HOBs, and CAFs. Mean ± SE (N = 2 technical replicates and N = 3 biological replicates 
for MSCs and HOBs, and N = 2 technical replicates and N = 2 biological replicates for CAFs); (B) ACCN4 and GPR65 mRNA analysis of 
MSCs after 6 hours of culture in acidic medium. Mean ± SE (N = 2 technical replicates and N = 3 biological replicates); **p < 0.01, and 
*p < 0.05.
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of IL6 and BDNF as well as high IL6 level alone were 
significantly correlated in patients with breakthrough pain 
vs patients without breakthrough pain (p=0.0131 and 
p=0.0354, respectively; Figure 8C). High serum levels 
of IL6 and IL8 in patients with cancer are assumed to 
be derived from strong local secretion from tumors. In 
contrast to that assumption, in vitro analysis and deep-
sequencing screens including breast cancers (MCF7, 
T47D, and SKBR3 cell lines, data not shown), revealed 
consistent and strong expression of IL6 and IL8 by 
mesenchymal stromal cells and not by carcinoma cells, 
particularly when the mesenchymal cells were exposed to 
extracellular acidosis.
We looked for IL8 localization in tissue sections 
of BM from breast carcinoma and also in relation 
to intratumoral acidosis. We used cytokeratin and 
vimentin staining to identify the carcinoma cells and the 
surrounding mesenchymal stroma, respectively (Figure 9, 
first string from the top). We used LAMP2 staining as a 
marker of the acidic microenvironment [19], which was 
confined to the carcinoma cells, as indicated by a complete 
overlapping with the cytokeratin signal (Figure 9, yellow 
color in the merged image of the second string). Similarly, 
IL8 localized very closely to the LAMP2-positive tumor 
area, but with only a partial overlap (Figure 9, third 
string), possibly because IL8 is secreted close to the 
Figure 4: Short exposure to acidosis induces the release of inflammatory and nociceptive mediators in mesenchymal 
stromal cells of the BM microenvironment (deep sequencing of MSCs). (A) Heat map representation of the fold increase, by 
deep-sequencing analysis, of the mRNA levels of inflammatory and nociceptive mediators of normal stromal cells (4 lots of BM-MSCs) 
after short-term acidosis (pH 6.5) compared to physiological medium (pH 7.4). Colors on the heat map indicate the log2 ratios of expression 
(representing normalized read counts). Red, upregulation; green, downregulation; (B) Short-term acidosis activates inflammatory and 
nociceptive mediators in normal mesenchymal cells. Graphical representation of transcriptional fold increases after short-term acidosis (24 
hrs at pH 6.5) of inflammatory and nociceptive mediators genes, in respect to physiological medium (pH 7.4), in normal stromal cells as 
revealed by deep-sequencing analysis. Mean ± SE (N = 4 lots of BM-MSCs). *p < 0.05.
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Figure 5: Short exposure to acidosis induces the release of inflammatory and nociceptive mediators in mesenchymal 
stromal cells of the BM microenvironment (MSCs, HOBs, and CAFs). (A) mRNA analysis of inflammatory and nociceptive 
mediators. Mean ± SE (N = 3 lots with N = 2 technical and N = 2 biological replicates each lot for MSCs and HOBs, and only 1 lot for CAFs 
with the same number of biological and technical replicates) ***p<0.001, **p < 0.01, and *p < 0.05; (B) mRNA expression of BDNF and 
NGF in bmMDA cells in respect to HOBs exposed for 24 hrs to low pH (= K, 100%); (C) ELISA quantification of IL6 and IL8 in the culture 
supernatants. Mean ± SE (N = 3 lots with N = 2 technical each lot for MSCs and HOBs, and only 1 lot for CAFs with N = 2 technical and 
N = 2 biological replicates) **p < 0.01 and *p < 0.05.
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acidic area of the BM microenvironment and mostly by 
untransformed mesenchymal stromal cells. The IL8 and 
cytokeratin staining only a partially overlapping (Figure 
9, fourth string), as was more clearly evident at a higher 
magnification (Figure 9, fifth string).
DISCUSSION
The identification of novel therapies that specifically 
and better target the pathogenic mechanism of CIBP more 
effectively than the currently available therapies is an 
urgent challenge. Within that context, the acidification of 
the interstitial pH of BM microenvironment into acidic 
values might play a major role because sensor neurons in 
the bone express acid-sensing nociceptors [20].
Recent studies suggest that CIBP is directly caused by 
bone resorption due to proton secretion by bone-resorbing 
osteoclasts, the altered metabolism of highly glycolytic 
and acidifying tumor cells, and the tumor-promoted 
inflammation that further enhances tissue acidosis [20, 
21]. We analyzed and confirmed the acidification activity 
of carcinoma cells, with particular regard for those that 
form BM. As a preclinical model, we used a subclone 
of the triple-negative breast carcinoma cell line MDA-
MB-231, which has a higher tendency than the parental 
cells to form osteolytic lesions in xenografts [16]. The 
bmMDA cells showed a greater ability and aptitude than 
the parental cells to secrete protons and to express ion/
proton transporters related to the acid-base balance (CA9, 
MCT4, and V-ATPase V1G1). The increased acidification 
Figure 6: Short-term acidosis activates the expression of inflammatory mediators in BM-associated mesenchymal 
cells. Graphical representation of mRNA expression over the time, starting from the acidosis exposure (medium at pH 6.8), of IL6 and IL8 
(A) and of NF-κB transcription factors (B) in normal stromal cells, as revealed by Q-RT-PCR analysis. Mean ± SE (for MSC and HOB, N = 
3 different lots, and for each lot, N =2 biological replicates, and N = 2 technical replicates; for CAF N = 1 lot, N = 2 biological replicates, N 
= 2 technical replicates). ***p<0.001, **p<0.01, and *p<0.05 versus the expression of the specified gene at the timing immediately before 
medium change with acidic medium in the same cells.
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activity derives from a high rate of glycolysis, as indirectly 
suggested by higher GLUT-1 expression and lactate release. 
The glycolytic activity and the extracellular acidification 
potential of both bmMDA cells and MDA cells were 
further enhanced by hypoxia which was not unexpected 
because low oxygen tension further promotes glycolysis. 
The bone marrow is a quite hypoxic tissue (1-6% O2) [22], 
and hypoxia is a crucial microenvironmental factor that 
provides a platform for circulating breast carcinoma cells 
to colonize the bone and form BM [23]. Our data are in 
agreement with previous studies showing that the tendency 
of breast carcinoma to invade and form distant metastases 
strongly depends on tumor acidification [15], and on highly 
acidic lysosomes [24]. The acidification of extracellular 
space is a selective advantage in bone because it enhances 
the activity of extracellular-matrix degradation by cancer-
secreted metalloproteinases [12, 25], and is associated 
with increased invadopodia formation [26] and with the 
induction of osteoclast-mediated bone resorption [27, 28], 
ultimately leading to an enhancement of erosion of the bone 
matrix [12]. Both tumor cells and osteoclasts acidify the 
extracellular space using V-ATPase, which is expressed on 
the lysosomal and plasma membranes [14, 24]. V-ATPase 
expression, and particularly that of the V1G1 subunit, which 
is highly expressed in bmMDA cells, has been related to 
tumor invasiveness [12, 24] and worse prognosis [29].
Previous attempts to target CIBP with bafilomycin 
A1, a toxic V-ATPase inhibitor, were successful in 
preclinical settings [30]. Therefore, we planned to target 
tumor extracellular acidification and acid-induced pain 
with omeprazole. Omeprazole and related drugs inhibit the 
grastric H+-ATPase and can also target V-ATPase at high 
concentration, through the binding to the V1A subunit [13, 
31, 32], and are widely prescribed as pivotal treatments in 
association with NSAIDs to reduce gastric side effects in 
advanced cancer patients. Once we confirmed in vitro that 
omeprazole significantly reduced lysosomal acidification 
of both osteoclasts and bmMDA cells, we treated BM and 
corresponding CIBP [33] with omeprazole intraperitoneally 
and at a higher dose than the standard dose conventionally 
used in humans. Omeprazole reduced pain 2 weeks before 
the inhibition of osteolysis with no evident side effects. It 
comes as no surprise that osteolysis was affected later than 
pain as the pathogenic mechanism of osteolysis in BM is a 
more long-lasting process than the neuronal stimulation. Our 
results on preclinical models suggest that the use of anti-acid 
or anti-glycolytic therapies may be effective for the future to 
treat CIBP in patients with bone metastasis. In this context, 
the use of i.g. proton pump inhibitors, as we explored, or of 
rapamycin, an already clinically available drug that has been 
demonstrated to decrease lactate production and acidosis by 
decreasing glycolysis [34, 35], is very promising.
Figure 7: Graphical summary of the proposed model of the induction of pain and of hyperalgesia and nociceptor 
sensitization in the BM microenvironment. In the BM microenvironment, carcinoma cells and tumor-induced osteoclasts pump in 
the extracellular space a high amount of protons that on one side stimulate ion channels on the membrane of the nociceptor terminal in bone, 
on the other side, promote the release of inflammatory and nociceptive mediators from the tumor-associated mesenchymal cells, including 
MSCs, HOBs, and CAFs that further enhance CIBP by promoting hyperalgesia and nociceptor sensitization.
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CIBP is a very complex phenomenon that is poorly 
understood. CIBP is the result of background pain 
combined with breakthrough pain that is rapid in onset 
and transient in nature. In contrast to background pain, 
breakthrough pain cannot be controlled by conventional 
analgesics [36] and, hence, interferes greatly with aspects 
of life [6]. Breakthrough pain has been more associated 
with CIBP than background pain. We speculated 
that, especially for the breakthrough component, pain 
stimulation and sensitization are related to the effect 
of acidity on the different cellular elements of the BM 
microenvironment. Indeed, in addition to being important 
algogenic mediators [7], protons might induce an 
inflammatory response in the tumor-associated reactive 
mesenchymal stroma, leading to the release of a plethora 
of inflammatory modulators at the injured site. Tissue 
acidification is commonly associated with inflammation 
because it acts as a driving force for mesenchymal stem 
cells during the regenerative process [37]. Similarly, 
in cancer, cells of mesenchymal origin are important 
components of the general host response to tumor-induced 
tissue damage, including tissue acidosis [38]. Osteoclasts 
[7, 39, 40] and cells of mesenchymal origin share with 
cells of neuronal origin the expression of acid-sensors. For 
Figure 8: Serum levels of IL6 and IL8 and pain. (A) IL6 and IL8 serum levels in BM patients versus healthy control subjects. Mean 
± SE (N = 36 for patients, and N = 9 for controls, *p<0.05); (B) Serum levels of BDNF in patients with BM in respect to healthy control 
donors. Mean±SE (n=22 for patients, and N = 9 for controls, **p<0.01); (C) IL6 and BDNF serum levels in respect to breakthrough pain 
in BM patients (yes, patients suffering for breakthrough pain; no, patients not suffering for breakthrough pain). Mean ± SE (N = 13 and N 
= 9, respectively, *p<0.05).
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Figure 9: IL8 localization in BM tissue samples. Immunofluorescence staining with different antigens and confocal analysis of 
a BM sections from a patient with a previous diagnosis of breast cancer. Intratumoral acidosis was revealed by LAMP2 staining. Cells 
were counterstained with Hoechst 33258 for nuclear blue signal (white bar corresponds to 50 μm, but in the last string at the bottom that 
corresponds to 10 μm).
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example, osteoblasts express ASICs [39] and TRPV1 [7]. 
Thus, mesenchymal cells can perceive a low extracellular 
pH like nociceptors can. We also confirmed the expression 
of ASIC3 and ASIC4 acid-sensing channels, as well as 
GPRs in all the mesenchymal cells analyzed, MSCs and 
osteoblasts, and CAFs that were directly isolated from 
BM of breast carcinoma. Furthermore, in osteoblasts, 
extracellular acidosis enhanced the expression of GPR65 
and ASIC4. To perform this type of in vitro assays, we 
used pH 6.8 since, although osteoclast activity might 
produce a pH around 3, this very high concentration of 
protons is compartmentalized in the Howship lacunae, 
and released in the extracellular space only at the end of 
the resorption activity, and immediately buffered with less 
acidic extracellular fluids.
Once mesenchymal cells detect extracellular acidosis, 
in addition to the release of metalloproteinases [41] that can 
concur to bone degradation, it may follow the activation and 
subsequent release of inflammatory mediators that might 
impact both on the tumor-related immune response and on 
pain induction (Figure 7). Indeed, we observed a consistent 
increase of CCL5, IL1b, IL6, and IL8. That induction was 
partially mediated by NF-kB pathway activation, as NF-
κB nuclear translocation was increased. The secretion of 
cytokines and chemokines has been clearly associated with 
the modulation of nociceptor activation and sensitization that, 
in turn, are responsible for the transmission of inflammatory 
pain and for evoking even greater responses [42, 43]. For 
a patient that means that a painful stimulus (allodynia) 
generates greater pain (hyperalgesia). Furthermore, recent 
studies have pointed out that cells of mesenchymal origin 
can directly release neuromodulators. For example, during 
bone damage, cartilage cells release nerve growth factor 
(NGF) [44]. Similarly, MSCs can release the neurotrophic 
factors NGF and BDNF [45] and, according to our data, 
their expression is potently induced by extracellular acidosis. 
NGF and BDNF regulate the survival, development, and 
function of sensory and sympathetic neurons, which are 
essential for the retention and generation of pain [43]. NGF 
evokes inflammatory hyperalgesia by promoting changes in 
the conductive properties of axons, by modulating the direct 
phosphorylation and membrane trafficking of TRPV1 by 
TrkA, and by modulating the expression of Na channels and 
ASIC [46]. Hence, the increased expression of ASIC4 that 
we observed in acid-induced MSCs might derive from an 
NGF autocrine pathway. Finally, it was clearly demonstrated 
in a rat model of CIBP that BDNF induces and maintains 
hypersensitivity [47]. In conclusion, according to our results, 
it is possible to assume that in patients with BM and suffering 
for pain, CIBP is also mediated by extracellular environment 
that in bone, in respect to the primary site, is particularly 
more acid due to the presence of both active tumor cells and 
osteoclasts, and is possibly differently innervated with acid-
sensitive nerve fibers. As a consequence of the alterations 
of the tumor microenvironment, the acid-induced release of 
inflammatory mediators and neuromediators also possibly 
explains the lack of responsiveness to conventional anti-
analgesic drugs in patients with BM and with breakthrough 
pain. Hence, in addition to anti-acid strategies, the use of anti-
NGF antibodies that are in the clinical phase of development 
for pain relief could be explored [48]. In agreement with 
our hypothesis, human studies indicated that the tumor 
microenvironment causes an abnormal remodeling of nearby 
sensory fibers, which is perceived as pain by patients [43]. 
Furthermore, previous literature reported high circulating 
levels of IL6 and IL8 in patients with BM [49], and that 
patients suffering from pain with advanced breast cancer have 
high systemic levels of the inflammatory mediators TNF, 
IL-1b, and IL6 [50]. Similarly, serum concentration of IL6 
and IL8 in patients with bone metastasis of breast, lung and 
undefined carcinoma that we enrolled had significantly higher 
levels for IL6 and IL8 than healthy controls.
To specifically assess the correlation between 
biomarkers in clinical samples and the biomarkers that we 
identified in mesenchymal cells in vitro, we quantified the 
serum levels of BDNF; however, those showed an opposite 
trend possibly because low levels of BDNF have been 
associated with depression and anxiety, which are quite 
common in patients with BM [51, 52]. Despite that, we 
found a trend of increased BDNF and a significant increase 
of IL8 in patients with breakthrough pain. Furthermore, 
when we considered IL6 together with BDNF, the 
combined high serum levels of those two biomarkers were 
significantly correlated with breakthrough pain.
Finally, the analysis of tissue sections of BM from 
breast carcinoma suggest that carcinoma cells are highly 
acidic, as demonstrated by the strong LAMP2 staining [19] 
in carcinoma cells, and furthermore, that IL8 appeared to 
be secreted for the most part by the mesenchymal stroma, 
close to the acidic area of the tumor, rather than by the 
tumor itself. Therefore, the higher levels of IL8 in patients 
with advanced cancer with BM and breakthrough pain 
possibly and partially originate from the mesenchymal 
stroma adjacent to the tumor cells and within the acidic 
microenvironment.
In conclusion, we have pointed out for the first time 
that intratumoral acidosis and the mesenchymal stromal 
reaction to tumor-associated acidosis might trigger CIBP, 
especially in BM, underlining once more that cancer-
associated fibroblasts and mesenchymal stromal cells 
coming from the host are of the foremost importance in 
cancer progression. With this study, we offer intratumoral 
acidosis as a promising target for novel and more effective 
palliative treatments for patients with advanced cancer.
MATERIALS AND METHODS
Reagents
Unless otherwise indicated, all reagents were 
obtained from Sigma: IMDM, penicillin, streptomycin, 
Trizol, unbuffered RPMI-1640 (Life Technologies); anti-
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fibroblast magnetic microbeads (Miltenyi Biotech); FBS, 
DMEM (Euroclone); glucose (Merk); MuLV Reverse 
Transcriptase (Applied Biosystems); RANKL, M-CSF 
(Peprotech); nitrocellulose membrane, D-luciferin 
(Thermo Fisher Scientific); BCA protein assay, Restore 
Western Blot Stripping buffer, Pierce ECL 2 Western 
Blotting Substrate (Pierce); TruSeq RNA Sample Prep 
Kit v2, Cycle Sequencing v4 regents (Illumina); Human 
IL6 DuoSet ELISA Kit, Human CXCL8/IL8 Quantikine 
ELISA Kit, Human Free BDNF Quantikine ELISA kit 
(R&D Systems Inc.). The antibodies used were: anti-rabbit 
Alexafluor, anti-mouse Alexafluor (Molecular Probes); 
Anti-MCT4 (sc-50329), anti-TBP (sc-204, Santa Cruz 
Biotechnology); anti-cytokeratin (M0821, Dako); anti-
cytokeratin-TRITC (41-9003, Affimetrix eBioscience); 
anti-LAMP2 (HPA029100); anti-IL8 (AB18672, Abcam); 
anti-vimentin (sc-6260, Santa Cruz Biotechnology); 
omeprazole (Sandoz); ketamine (MSD Animal Health Srl). 
Horseradish peroxidase-conjugated anti-mouse and anti-
rabbit were obtained from GE Healthcare.
Cell cultures
SH-SY5Y and MDA-MB-231 (MDA) cell lines 
were purchased from the American Type Cell Culture 
Collection (ATCC). The subclone (bmMDA) was 
previously derived from the parental MDA cell line [16, 
53]. We used mesenchymal stromal cells (MSCs) from 
bone marrow (BM-MSCs, 5 lots, Lonza) and from adipose 
tissue (AD-MSCs, 1 lot, ATCC), osteoblasts (HOBs, 1 lot, 
VWR International PBI) from healthy donors, and cancer-
associated fibroblasts (CAFs) as models of the human 
mesenchymal stroma of BM.
Human skin fibroblasts (Fb, 2 lots) were provided 
by the Japanese Collection of Research Bioresources. We 
isolated CAFs from BM biopsies using anti-fibroblast 
magnetic microbeads after obtaining signed informed 
consent and approval from the Rizzoli Orthopaedic 
Institute Ethical Committee (n. 0037602 of 14.11.2013). 
To obtain CAFs, we mechanically minced BM samples 
of breast carcinoma, and the obtained cell suspension 
was then seeded. When semi-confluence was reached, 
after cell trypsinisation, we used anti-fibroblast magnetic 
microbeads and MiniMACS™ separation (Miltenyi 
Biotec). CAF phenotype was confirmed by the analysis 
of smooth muscle alpha (α)-2 actin (ACTA2) and 
Fibroblast Activation Protein Alpha (FAP) expression 
in respect to normal human skin fibroblasts, at mRNA 
level (Supplementary Figure 2, *p=0.0209 for both 
ACTA2 and FAP), with Q-RT-PCR. Osteoclast cultures 
were derived from buffy coats of healthy donors (AVIS, 
Bologna) [54, 55]. To obtain osteoclast cultures, buffy 
coats were collected after their expiration date (1 
days after harvesting). Peripheral blood mononuclear 
cells (PBMC) from healthy donors were layered on 
Ficoll-Hystopaque gradient. The isolated mononuclear 
precursors were then seeded in 8-well chamber slides 
(3x106 cells/cm2) in DMEM supplemented with glucose 
[25 mM], 10% characterized FBS, plus penicillin [20 U/
mL], streptomycin [100 mg/mL]. After 1 h, non-adherent 
cells were removed and replaced with new medium 
added with RANKL [50 ng/mL] and M-CSF [10 ng/mL] 
(differentiation medium). In order to verify osteoclast 
differentiation, after 5 to 7 days of cell culture, cells 
were analyzed for tartrate-resistant acid phosphatase 
(TRAP) activity by Acid Phosphatase Leukocyte assay 
and nuclei were stained with Hoechst 33258. Only TRAP 
positive cells with more than 3 nuclei were considered as 
osteoclasts.
MDA, bmMDA, and SH-SY5Y were maintained 
in complete IMDM, MSCs in complete Alpha-MEM, 
HOBs and CAFs in complete DMEM, and osteoclasts 
in complete DMEM high glucose medium. Cells 
were cultured at 37°C, 5% CO2. Complete media 
were supplemented with 10% FBS, plus 100 units/mL 
penicillin, and 100 mg/mL streptomycin. Unless otherwise 
indicated, primary cultures and cell lines were maintained 
at pH 7.4. To create acidic conditions, we adjusted the pH 
of the medium to 6.5 or 6.8 using specific concentrations 
of sodium bicarbonate as previously described [18]. At 
the end-point of each experiment, we measured the pH of 
the culture supernatants to confirm the maintenance of the 
prefixed pH values during the incubation period.
We used only MSCs, HOBs, and CAFs that had 
been passaged no more than six times. Osteoclasts were 
used only at passage 0.
Q-RT-PCR
Total RNA was extracted using Trizol and reverse 
transcribed using MuLV Reverse Transcriptase. Specific 
genes were amplified by Real-Time PCR. The primers 
and probes are listed in Table 1. For RNA isolation under 
hypoxia, we incubated the cells with 1% O2 (In vivo 2-400 
hypoxic incubator; Ruskin Technologies) for 24 h. Real-
Time PCR was performed by amplifying 1 μg of cDNA 
using the Light Cycler instrument and the Universal Probe 
Library system (Roche Applied Science). Probes and 
primers were selected using the web-based assay design 
software (ProbeFinder: http://www.roche-applied-science.
com). Results were normalized to Hydroxymethylbilane 
synthase (HMBS) or beta-Actin (β-actin), according to the 
2−ΔΔCT method. We performed each assay with at least two 
technical replicates and two biological replicates.
Western blotting
We lysed the cells at semi-confluence with boiling 
buffer containing 1% sodium dodecyl sulfate (SDS), 
Tris pH 7.4 (20 mM), 2-Mercaptoethanol (5%), and 
sodium orthovanadate (1 mM). We then quantified the 
protein content by BCA assay. Equal amounts of proteins 
were subjected to SDS-PAGE, blotted on nitrocellulose 
membranes, and then incubated with specific primary 
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Table 1: Probes and primers.
Gene Full name Accession Number Primers Probe
HMBS Hydroxymethylbilane synthase NM_000190.3 F = tgtggtgggaaccagctc
R = tgttgaggtttccccgaat
26
CA9 Carbonic anhydrase 9 NM_001216.2 F = tgcctatgagcagttgctgt
R = ccagtcctgggacctgagt
73
GLUT1 Glucose transporter-like protein 
I
AY034633.1 F = ggttgtgccatactcatgacc
R = cagataggacatccagggtagc
67
MCT4 Solute carrier family 16 member 
4
NM_001206952.1, 
NM_004207.3, 
NM_001042422.2, 
NM_001042423.2, 
NM_001206950.1, 
NM_001206951.1
R = gagtttgggatcggctacag
F = cggttcacgcacacactg
58
BDNF Brain-derived neurotrophic 
factor
NM_170731.3, 
NM_170732.3, 
NM_170733.2, 
NM_170734.2, 
NM_170735.4, 
NM_001709.3
R = gtaacggcggcagacaaa
F = gaccttttcaaggactgtgacc
86
NGF Nerve growth factor NM_002506.2 R = agtggtcgtgcagtccaag
F = ggacattacgctatgcacctc
42
CCL5 Chemokine (C-C motif) ligand 5 NM_002985.2 F = tgcccacatcaaggagtattt
R = ctttcgggtgacaaagacg
59
IL1B Interleukin 1, beta NM_000576.2 R = aaagcttggtgatgtctggtc
F = ggacatggagaacaccacttg
10
TNF Tumor necrosis factor NM_000594.2 R = cagcctcttctccttcctgat
F = gccagagggctgattagaga
29
IL6 Interleukin 6 NM_000600.3 F = gatgagtacaaaagtcctgatcca
R = ctgcagccactggttctgt
40
IL8/CXCL8 C-X-C motif chemokine ligand 
8
NM_000584.3 F = gagcactccataaggcacaaa
R = atggttccttccggtggt
72
ACCN4 Acid sensing ion channel 
subunit family member 4
NM_182847.2 R = gacagatgggcctgttcatt
F = ccatacccgcttcagtcg
67
ACCN3 Acid sensing ion channel 
subunit 3
NM_004769.2 R = ccttgtgggcctgagaac
F = cccatgccacccctagta
43
GPR65 G protein-coupled receptor 65 NM_003608.3 R = gggcagatcgccttaggt
F = caggtctggcacatttttga
54
GPR4 G protein-coupled receptor 4 EU432116.1 R = ttccgccatccctctacat
F = ccacagagccaggcagtt
44
ATP6V1B2 ATPase H+ transporting V1 
subunit B2
NM_001693.3 R = tggccgaagacttccttg
F = ccgaaatgccagtctgaatc
6
ATP6V0C ATPase, H+ transporting, 
lysosomal 16kDa, V0 subunit c
NM_001694.2 R = ttcgtttttcgccgtcat
F = ccactgggatgatggacttc
76
ATP6V1G1 ATPase H+ transporting V1 
subunit G1
NM_004888.3 R = tcagtctcaggggattcagc
F = tcagcctgagcttcttctttg
75
(Continued )
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and secondary antibodies. The reactions were revealed 
by Pierce ECL 2 Western Blotting Substrate. To detect 
different proteins on the same blot, we stripped the 
nitrocellulose membranes with Restore Western Blot 
Stripping buffer and then reprobed them. We quantified 
the signals using the VisionWorksLS Analysis Software 
(Biospectrum, UVP). The results presented are 
representative of four biological replicates.
Lactate assay
For the lactate assay, we plated 6x104 cells/cm2 on 
12-well plates in complete IMDM. After 24 h, we changed 
the media with new media containing 2% FBS. After 48 
h, we harvested the culture supernatants and measured the 
L-lactate concentration using the EnzyChrom L-Lactate 
Assay Kit (BioAssay Systems, ECLC-100). For the 
hypoxic condition, we incubated the cells for 48 h after 
seeding as previously described. Normalization was 
performed with respect to the total protein content, as 
measured by BCA protein assay. The experiments were 
performed with four technical replicates.
pHMed assay
We measured the pH of the culture medium using 
a micro-electrode [18]. Cells were (16×106 cells) washed 
twice in pHMed solution (80% normal saline, 10% 
unbuffered RPMI-1640 and 10% FBS), and incubated 
in pHMed in suspension for 3 hrs at 37°C. Cells were 
then centrifuged (10 min at 500xg), and supernatant was 
collected for pH measurement. pH was immediately 
measured by a digital pH-meter (pH 301, HANNA 
Instruments). The difference of pH of pHMed solution alone 
(negative control) and the cell supernatants was analyzed. 
The experiment was repeated with six biological replicates.
Confocal spectral analysis of the lysosomal pH
We used the emission spectra of the pH-sensitive 
dye acridine orange to measure slight pH variation in the 
intracellular acidic organelles [13]. Twenty-four h after 
seeding, cells were incubated at pH 6.5 for 30 min with or 
without omeprazole (100 μM) and then washed and analyzed. 
Osteoclasts at 7 days of culture or MDA or bmMDA at 
semi-confluence were incubated with acridine orange [0.5 
μg/mL] for 15 min. After one wash, x,y emission spectra 
from a confocal section within a living cell were recorded 
using a confocal laser microspectrofluorimeter (Nikon, TI), 
equipped with an argon-ion laser. Cells were focused with 
x40 lens, 1.3 NA (S Fluor, Nikon) and excited at 457 nm, and 
the resulting fluorescence emission in the 500-700 nm range 
was collected. For intracellular measurements of acridine 
orange emission the pinhole size was fixed to a diameter 
of 54 μm. To characterize the profile of acridine orange 
emission spectra, the red band contribution (R%) within the 
whole emission spectrum has been calculated as follows: 
R%=100*I655/ (I655 + I530) where I655 and I530 are the green 
(520-540 nm) and the red (645-665 nm) integrated emission 
intensities, respectively. The R% was calculated for all the 
acidic organelles within a single cell, and the average R% of 
acidic organelles of one single cell was considered.
We averaged of the measured signals from all the 
lysosomes in at least fourteen single cells.
In vivo study
Procedures involving animals and their care were 
conducted with institutional approval and conformed 
to national and international laws and policies (EEC 
Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; 
Italian Legislative Decree 116/92, Gazzetta Ufficiale della 
Repubblica Italiana n. 40, Feb. 18, 1992; NIH guide for 
the Care and Use of Laboratory Animals, NIH Publication 
No. 85–23, 1985). Four-week-old female BALB/cnu/nu 
mice were anaesthetized with ketamine/xylazine (75 mg/
Kg body weight + 15 mg/Kg body weight, respectively), 
injected monolaterally with bmMDA (5×104 cells/10 
µl PBS) in the medullar cavity of the left tibia and then 
treated i.p. with vehicle (0.9% NaCl) or omeprazole (40 
mg/kg body weight). Treatment was administered 5 days 
per week for 4 weeks, starting the day after tumor cells 
inoculation.
Gene Full name Accession Number Primers Probe
ACTA2 Actin, alpha 2, smooth muscle, 
aorta
NM_001141945.1, 
NM_001613.2
R = ctgttccagccatccttcat
F = tcatgatgctgttgtaggtggt
58
FAP Fibroblast activation protein, 
alpha
NM_004460.2 R = tggcgatgaacaatatcctaga
F = atccgaacaacgggattctt
19
NFKB1 Nuclear factor kappa B subunit 1 NM_003998.3 F = cctggaaccacgcctcta
R = ggctcatatggtttcccattta
49
RelA RELA proto-oncogene, NF-kB 
subunit
NM_021975.3 F = actgtgtgacaaggtgcagaa
R = cacttgtcggtgcacatca
64
RelB RELB proto-oncogene, NF-kB 
subunit
NM_006509.3 F = gattgtcgagcccgtgac
R = ccacgccgtagctgtcat
4
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To calculate the entity of osteolytic lesions we 
anaesthetised mice as described, laid them flat on a 
x-ray-sensitive film and exposed them in an x-ray cabinet 
(Faxitron, Tucson, AZ, USA) to obtain standard 2D x-ray 
scans. After developing the films, we took high resolution 
images of them and analysed osteolytic lesions by 
manually selecting the osteolytic areas using the software 
ImageJ (NIH).
For CIBP assessment, we tested the mice every 
week through the Linton instrumentation incapacitance 
tester (Supplementary Figure 3) [54]. Briefly, mice were 
placed in the measurement chamber in an upright position, 
with the non-inoculated and inoculated limbs placed 
on 2 separate micro-scales. 5 measurements of weight 
distribution between the two hindlimbs were carried out. 
Changes in hind paw weight distribution between the 
right (tumor bearing) and left (contralateral control) limbs 
were utilized as an index of joint discomfort due to tumor 
growth. The change in hind paw weight distribution was 
calculated by determining the difference (expressed as 
percent difference) in the amount of weight (g) between 
the left and right limbs.
Illumina genome analyzer sequencing and data 
analysis
mRNA expression was evaluated by extracting total 
RNA using Trizol from cells cultured at pH 6.5 and ph 
7.4 for 24 h. We quantified the RNA using a Bioanalyzer 
(Agilent). The RNA integrity numbers (RIN) and A260/
A280 ratios were all equal to 10, and greater than 1.8, 
respectively. We converted the total RNA to a library of 
template molecules for high-throughput DNA sequencing 
using the TruSeq RNA Sample Prep Kit v2. We quantified 
the library using a Bioanalyzer. Library (7 pM) was 
subjected to cluster amplification to cluster generation 
on a Single Read Flow Cell v4 with a cluster generation 
instrument (Illumina). Sequencing was performed on 
a Genome Analyzer GAIIx for 76 cycles using Cycle 
Sequencing v4 regents. Image analysis and base calling 
were performed using Off-Line Basecaller Software 
1.6 (Illumina). Reads were aligned using ELAND v2 
of CASAVA Software 1.7 with the sequence data sets. 
Human genome build 19 (hg19) were downloaded from 
University of California, Santa Cruz genome browser 
(http://genome.ucsc.edu/) as the analytic reference. 
Transcript coverage for every gene locus was calculated 
from the total number passing filter reads that mapped, by 
ELAND-RNA, to exons. These analyses were performed 
using default parameters. The advanced analysis for 
quantification with Quantile normalization algorithm 
was performed using Avadis NGS software (version1.5, 
Strand Scientific Intelligence Inc., San Francisco, CA). 
The filtering was performed using default parameters.
We registered the obtained data at DDBJ/EMBL/
GenBank (DRA004087 and DRA004091).
ELISA assay
We quantified IL6, IL8, and BDNF in culture 
supernatants and serum samples using the Human IL6 
DuoSet, Human CXCL8/IL8 and Free BDNF Quantikine 
ELISA Kits, respectively. To generate the supernatants, 
we seeded cells at 1.5x104 cells/cm2, and after adhesion, 
incubated them for 20 h in Alpha-MEM plus 0.1% FBS. 
We then washed the cells and incubated them in acidic 
(pH 6.8) or physiological (pH 7.4) Alpha-MEM plus 
0.1% FBS. After 24 h, the supernatants were collected. 
Normalization was performed with respect to the total 
protein content measured by BCA protein assay. We 
obtained blood samples from nine healthy controls and 36 
patients with newly diagnosed BM at the time of diagnosis 
(7 breast carcinomas, 10 from lung carcinomas, n. 19 from 
undefined carcinoma) and that were seen at the Rizzoli 
Orthopaedic Institute or were enrolled from the ANT 
foundation in Bologna from February 2014 through July 
2016. To identify patients suffering from breakthrough 
pain at presentation, we administered a pain questionnaire 
to a subgroup of 22 patients that suffering from pain 
(Appendix 1). Blood and pain questionnaires were 
collected at clinical presentation, before surgical treatment 
of the bone lesion, with signed informed consent and with 
institutional ethical committee approval (n. 0037602 of 
14.11.2013). Breakthrough pain was considered short 
duration (less than 15 min) pain perceived in the last 24 h 
that significantly affected the quality of life [6].
Immunofluorescence
We obtained tissue samples from 1 patient that was 
seen at the Rizzoli Orthopaedic Institute and with newly 
diagnosed BM at the time of diagnosis with a past diagnosis 
of breast carcinomas. Tumor tissue was collected during 
surgical treatment of the bone lesion, with signed informed 
consent and with institutional ethical committee approval 
(n. 0037602 of 14.11.2013). We embedded BM samples 
at optimal cutting temperature (OCT) and frozen them 
on dry ice before sectioning. We sectioned the samples 
at 10 μm and put them on a glass slide covered with 2% 
acetone in saline. The slides were stored at -80°C until 
immunostaining. Defrosted sections were permeabilized 
for 15 min with PBS containing 0.1% TritonX-100, 
blocked with 1% BSA for 1 h, and incubated with primary 
antibodies overnight. Then the sections were incubated with 
fluorochrome-conjugated secondary antibodies and Hoechst 
33258 for nuclear staining and mounted and observed by 
confocal microscopy (Nikon TI-E).
Statistical analysis
Because of the small number of observations, 
we did not consider the data to be normally distributed 
and therefore used non-parametric tests. We performed 
statistical analysis using the StatView 5.0.1 software (SAS 
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Institute Inc.). For the difference between two groups, we 
used the Mann-Whitney U test. For the correlations between 
breakthrough pain and the simultaneous presence of high 
serum IL6 and high BDNF levels, we used the Fisher’s 
exact test. We considered IL6 and BDNF levels high when 
they were above the 40th percentile of the patient group 
with pain (0 pg/mL and 22,519 pg/mL, respectively). For 
the in vivo studies Student’s t-test was used with α=0.05. We 
expressed values as the means±SE and only p<0.05 values 
were considered to be statistically significant.
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